Category - New Drugs
Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan) for the Reduction of Proteinuria in Primary IgA Nephropathy (IgAN)
FDA Approves Zurnai (nalmefene hydrochloride) Auto-Injector for the Emergency Treatment of Known or Suspected Opioid Overdose
Apellis Announces U.S. FDA Approval of the Empaveli Injector, a Device to Streamline Self-Administration
FDA Approves Technegas (Technetium Tc 99-m Labeled Carbon) Radioactive Diagnostic Agent
FDA Approves Rivfloza (nedosiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
FDA Approves Tofidence (tocilizumab-bavi), a Biosimilar to Actemra
FDA Approves Exxua (gepirone) for the Treatment of Major Depressive Disorder in Adults
FDA Approves Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) for the Treatment of Late-Onset Pompe Disease